At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Deucravacitinibdrug
Likely dose
Deucravacitinib 6 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Deucravacitinib (BMS-986165) in the Treatment of Lichen Planopilaris
In Brief
A Phase 2 clinical trial evaluating Deucravacitinib for Lichen Planopilaris. Completed, enrolled 12 participants across 2 sites.
Detailed Summary
The purpose of this clinical research study is to learn more about the use of Deucravacitinib in the treatment of Lichen Planopilaris.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLichen Planopilaris
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
202420252026
First PostedOct 2023
Enrollment StartNov 2023
Primary CompletionMay 2024
Study CompletionDec 2024
TodayJul 2026
First PostedOct 23, 2023
Enrollment StartNov 7, 2023
Primary CompletionMay 21, 2024
Study CompletionDec 24, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.7 years ago
Interventions
Deucravacitinibdrug
6 milligram (mg) orally administrated, twice daily